EDAP TMS S.A. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.82next fiscal year
Monitoring Framework
Key Performance Indicators
HIFU Business Revenue Quarterly11.6MTarget: 50000000 to 54000000
U.S. Focal One Procedure Volume Growth Quarterly5,300.0%Target: Maintain double-digit growth
Focal One System Shipments Quarterly11.0Target: Accelerate global placements
Watch Items
- Discontinued Operations Accounting TransitionTrigger: Q2 2026 Financial ReportingAction: Verify the formal classification and financial separation of the legacy ESWL and Distribution segments from continuing robotic focal therapy operations.
- Shareholder Approval for Legal Name ChangeTrigger: Upcoming General Meeting of ShareholdersAction: Monitor voting results to officially change the legal entity name from EDAP TMS S.A. to FocalTherics.
- Clinical Expansion and Regulatory MilestonesTrigger: Deep Infiltrating Endometriosis and New IndicationsAction: Track clinical trial progress and regulatory clearances to expand the addressable market beyond prostate cancer.
Research as of 19 Jun 2026